News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Concert Pharmaceuticals, Inc. (CNCE) Reports Second Quarter 2014 Financial Results And Provides Company Update


8/12/2014 8:45:24 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2014.

“The clinical and regulatory successes we have realized in the recent months are important to enabling our programs to advance into and through later stage clinical trials,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “Our proprietary drug candidates, including CTP-354 for spasticity, have the potential to achieve multiple development milestones in the second half of the year. Importantly, we plan to initiate a Phase 2 clinical trial for spasticity associated with spinal cord injury later this year. In addition, two of our drug candidates in development with collaborators have achieved recent clinical advancements which continue the strong momentum with these programs.”

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES